Biodesix lands $17.8M Series F funding round

BOULDER — Diagnostic test-maker Biodesix Inc., has raised a Series F funding round worth nearly $17.8 million, according to a recent filing with the U.S. Securities and Exchange Commission.

Biodesix CEO David Brunel couldn’t be reached for comment Tuesday.

The round includes the conversion of convertible promissory notes. The company disclosed in October that it had raised $8.6 million in convertible debt. Brunel said then that company officials were “watching the markets” and monitoring the company’s own progress before settling on a price for the new equity funding round.

SPONSORED CONTENT

How Platte River Power Authority is accelerating its energy transition

Platte River Power Authority, the community-owned wholesale electricity provider for Northern Colorado, has a history of bold initiatives.

Biodesix makes a line of blood tests aimed at identifying which cancer patients could best benefit from various cancer drugs, because most cancer drugs work only on specific sets of the population. In essence, the tests help get the right drugs to the right patients.

At the time of the debt raise in October, Brunel said that new cash would go toward continued support of sales and marketing of its Veristrat product, as well as development of new tests for immunotherapy.

Veristrat has about 120 employees, about half of which are in Boulder.